ALNY
ALNY
Positions held
Your positionsALNY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value?
2026-10-08 · Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-08 · Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
2026-10-08 · RBC Lowers Price Target on Alnylam Pharmaceuticals to $345 From $350, Keeps Outperform Rating
2026-10-07 · ETON Stock Surges 108% in Six Months: Here's What You Need to Know
2026-10-06 · PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
2026-10-02 · 3 Great Healthcare Stocks To Own In October 2026
2026-09-28 · 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
2026-09-28 · 18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
2026-09-25 · RNAi drug specialist ADARx raises $446M IPO
2026-09-22 · Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Price (daily)
Full chart · RSI · MACD · patterns